Anna Roca, Gambia
Medical Research Council Unit Disease Control and EliminationAuthor Of 2 Presentations
FOLLOWING A DECADE OF PCV IN THE GAMBIA SHOULD A DECLINE IN RESISTANCE BE ANTICIPATED? (ID 1205)
- Muhammed Arafat Cham, Gambia
- Brenda Kwambana-Adams, United Kingdom
- Madikay Senghore, United States of America
- Effua Usuf, Gambia
- Archibald Worwui,
- Rasheed Salaudeen, Gambia
- Lesley McGee, United States of America
- Stephen D. Bentley, United Kingdom
- Robert F. Breiman, United States of America
- Anna Roca, Gambia
- Grant Mackenzie, Gambia
- Martin Antonio, Gambia
INVASIVE PNEUMOCOCCAL DISEASE IN THE GAMBIA: TRENDS IN SEROTYPE PREVALENCE PRE AND POST PCV INTRODUCTION (ID 661)
Abstract
Background
The introduction of PCV7 in August 2009 and PCV13 in May 2011 in The Gambia resulted in decline of invasive pneumococcal disease (IPD) incidence by 55% in the Eastern region although changing serotypes are emerging.
Methods
We retrospectively compared disease and serotype prevalence pre-PCV (January 2005-December 2009) and post-PCV (January 2012 - December 2015) periods for IPD in the Western region of the country
Results
Out of 12,454 blood and 979 CSF cultures analysed, 6.8% (847/12454) blood and 6.9% (68/979) CSF were clinically significant pathogens. The prevalence of IPD for suspected bacteraemia was 1.8% (218/12454) constituting 25.8% (218/846) of all confirmed cases and 3.9% (38/979) for meningitis constituting 55.9% (38/68). When compared by vaccine period, a significant drop across all age groups post-PCV was found, decreasing from 32.4% (160/494) to 16.5% (58/352) for bacteraemia and from 67.3% (33/49) to 26% (5/19) for meningitis.
Serotype data was available for 86.3% (221/256) and decrease in PCV13 vaccine serotypes from 62.2% (120/193) to 41.3% (26/63). Concurrently increase in non-vaccine serotypes from 24.9% (48/193) to 42.8 % (27/63) was found with 12F accounting for 50%.
Conclusions
The PCVs have reduced IPD but serotype replacement is noted warranting surveillance and more intervention.